Philipp Beckhove
Overview
Explore the profile of Philipp Beckhove including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
5780
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Safi S, Benner A, Beckhove P, Muley T
Pulmonology
. 2025 Jan;
31(1):2447637.
PMID: 39773309
No abstract available.
2.
Baldwin J, Heuser-Loy C, Saha T, Schelker R, Slavkovic-Lukic D, Strieder N, et al.
Cell
. 2024 Sep;
187(23):6614-6630.e21.
PMID: 39276774
Mitochondrial loss and dysfunction drive T cell exhaustion, representing major barriers to successful T cell-based immunotherapies. Here, we describe an innovative platform to supply exogenous mitochondria to T cells, overcoming...
3.
Sanna F, Benesova I, Pervan P, Krenz A, Wurzel A, Lohmayer R, et al.
Front Immunol
. 2024 Aug;
15:1437224.
PMID: 39211051
IL-32 expression is important for pathogen clearance but detrimental in chronic inflammation, autoimmunity, and cancer. T cells are major IL-32 producers in these diseases and key mediators of pathogen and...
4.
Hussein A, Stamova S, Xydia M, Beckhove P
Cancer Cell
. 2024 Jun;
42(6):938-941.
PMID: 38861930
Cancer immunotherapy is a pillar of clinical oncology but only achieves long-term remissions in a minority of cases. In this issue, van Elsas et al. show that effective immunotherapy requires...
5.
Delacher M, Schmidleithner L, Simon M, Stuve P, Sanderink L, Hotz-Wagenblatt A, et al.
J Exp Med
. 2024 Jan;
221(2).
PMID: 38226976
CD8 T lymphocytes are classically viewed as cytotoxic T cells. Whether human CD8 T cells can, in parallel, induce a tissue regeneration program is poorly understood. Here, antigen-specific assay systems...
6.
Weidner L, Lorenz J, Quach S, Braun F, Rothhammer-Hampl T, Ammer L, et al.
Acta Neuropathol Commun
. 2023 Sep;
11(1):147.
PMID: 37697350
TSPO is a promising novel tracer target for positron-emission tomography (PET) imaging of brain tumors. However, due to the heterogeneity of cell populations that contribute to the TSPO-PET signal, imaging...
7.
Braun F, Rothhammer-Hampl T, Lorenz J, Pohl S, Menevse A, Vollmann-Zwerenz A, et al.
Cells
. 2023 Jul;
12(14).
PMID: 37508520
Conventional 2D cultures are commonly used in cancer research though they come with limitations such as the lack of microenvironment or reduced cell heterogeneity. In this study, we investigated in...
8.
Menevse A, Ammer L, Vollmann-Zwerenz A, Kupczyk M, Lorenz J, Weidner L, et al.
Acta Neuropathol Commun
. 2023 May;
11(1):75.
PMID: 37158962
Glioblastoma (GB) IDH-wildtype is the most malignant primary brain tumor. It is particularly resistant to current immunotherapies. Translocator protein 18 kDa (TSPO) is upregulated in GB and correlates with malignancy...
9.
Michaelides I, Kunzel J, Ettl T, Beckhove P, Bohr C, Brochhausen C, et al.
Eur Arch Otorhinolaryngol
. 2023 Mar;
280(6):2937-2944.
PMID: 36856809
Background: Adenoid cystic carcinoma (ACC) is a rare type of cancer commonly occurring in salivary glands. It is characterized by slow but infiltrative growth, nerve infiltration and overall poor prognosis,...
10.
Babl N, Hofbauer J, Matos C, Voll F, Menevse A, Rechenmacher M, et al.
Front Oncol
. 2023 Feb;
13:1107484.
PMID: 36776340
Introduction: The discovery of immune checkpoints and the development of their specific inhibitors was acclaimed as a major breakthrough in cancer therapy. However, only a limited patient cohort shows sufficient...